Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study-Reference-Cited by-同舟云学术

Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study

Published:2013-09-27 Issue:12 Volume:139 Page:2047-2056
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Maass Nicolai, ,Harbeck Nadia,Mundhenke Christoph,Lerchenmüller Christian,Barinoff Jana,Lück Hans-Joachim,Ettl Johannes,Aktas Bahriye,Kümmel Sherko,Rösel Siegfried,Wagner Steffen,Müller Lothar,Bischoff Joachim,Lübbe Kristina,Schwedler Kathrin,Schmidt Marcus,Bauerschlag Dirk,Nekljudova Valentina,von Minckwitz Gunter,Loibl Sibylle

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-013-1518-x.pdf

Reference16 articles.

1. Andre F, Campone M, O’Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 28:5110–5115

2. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30:2718–2724

3. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2630–2637

4. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529

5. Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LL (2012) Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 30:2919–2928

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The emerging role of osteoclasts in the treatment of bone metastases: rationale and recent clinical evidence;Frontiers in Oncology;2024-08-01

2. Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review;Breast Cancer Research;2024-05-22

3. The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer;Cancer Research;2024-05-15

4. Role of Altered Metabolic Microenvironment in Osteolytic Metastasis;Frontiers in Cell and Developmental Biology;2020-06-05

5. Current and Emerging Bone-Targeted Therapies for The Treatment of Bone Metastases From Solid Tumors;Encyclopedia of Bone Biology;2020